![]() |
市場調查報告書
商品編碼
1654642
全球電穿孔儀器市場 - 2025 至 2033 年Global Electroporation Instruments Market - 2025-2033 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
2024 年全球電穿孔儀器市場規模達到 2.5142 億美元,預計到 2033 年將達到 3.7404 億美元,2025-2033 年預測期內的複合年成長率為 4.5%。
電穿孔儀器是用於促進電穿孔的設備,電穿孔是一種向細胞施加短電脈衝以暫時增加其膜通透性的技術。這使得 DNA、RNA、蛋白質或藥物等物質能夠被引入細胞,而這個過程對於生物技術、基因工程和醫學中的各種應用至關重要。電穿孔廣泛應用於基因研究、藥物傳遞、疫苗接種和蛋白質生產,因為與傳統方法相比,它允許分子物質更有效、更直接地轉移到細胞中。這些儀器因其精確度、有效性以及處理多種細胞類型(包括真核細胞和原核細胞)的能力而受到高度重視。
受生物技術進步、研究活動的增加以及基因編輯和治療應用需求不斷成長的推動,電穿孔儀器市場正在經歷顯著成長。例如,2024年6月,博騰生物將MaxCyte cGMP級ExPERT GTx流式電穿孔儀引入其細胞治療平台,標誌著該公司成為中國第一家擁有該臨床級流式電穿孔系統的細胞治療CDMO。
促進因素與約束因素
科技進步日新月異
不斷進步的技術極大地推動了電穿孔儀器市場的成長,並預計在預測期內推動市場的發展。電穿孔已成為癌症治療的關鍵技術,尤其是透過電化學療法。該方法包括向腫瘤施加電脈衝,增加細胞膜通透性並允許化療藥物更有效地進入癌細胞。技術進步提高了該技術的精確度和安全性,為皮膚和皮下腫瘤患者帶來了更好的治療效果。
例如,2024 年 10 月,AngioDynamics 與倫敦大學學院醫院 (UCLH) 合作啟動了一項前瞻性註冊研究,評估奈米刀系統治療單灶中危前列腺癌的長期效果。此奈米刀系統使用不可逆電穿孔技術來治療腫瘤,透過傳遞高壓電脈衝在細胞膜上產生微小孔隙,從而導致可控細胞死亡,而不會損害周圍組織。
CRISPR-Cas9等基因編輯技術的發展增加了對電穿孔儀器的需求。電穿孔有助於將基因編輯成分有效地遞送到細胞中,從而推動研究和治療應用。這導致電穿孔儀器在基因工程和治療干預中的應用激增。
電穿孔儀器成本高
電穿孔儀器的高成本限制了其可及性和採用率,嚴重阻礙了市場的成長,尤其是對於預算有限的小型實驗室和研究機構。例如,新型電穿孔系統的成本通常在 3,000 美元到 20,000 美元之間,具體取決於型號、特性和能力。
電穿孔儀器的價格昂貴,只有資金充足的實驗室和研究中心才能購買,而較小的機構則無法投資此類技術。這種差異導致無法平等地獲得先進的研究工具,阻礙了市場的整體成長。高昂的設備成本可能導致研究項目和新療法開發的延遲,因為機構可能缺乏採購和維護這些儀器所需的資源。研究活動的放緩可能會阻礙該領域的科學進步和創新。
The global electroporation instruments market reached US$ 251.42 million in 2024 and is expected to reach US$ 374.04 million by 2033, growing at a CAGR of 4.5% during the forecast period 2025-2033.
Electroporation instruments are devices used to facilitate electroporation, a technique that involves applying short electrical pulses to cells to temporarily increase the permeability of their membranes. This allows for the introduction of substances like DNA, RNA, proteins, or drugs into the cell, a process that is essential for various applications in biotechnology, genetic engineering, and medicine. Electroporation is widely used in genetic research, drug delivery, vaccination, and protein production, as it allows for more efficient and direct transfer of molecular substances into cells compared to traditional methods. The instruments are highly valued for their precision, effectiveness, and ability to handle a variety of cell types, including both eukaryotic and prokaryotic cells.
The electroporation instruments market is experiencing significant growth, driven by advancements in biotechnology, increased research activities, and the rising demand for gene editing and therapeutic applications. For instance, in June 2024, Porton Advanced introduced the MaxCyte cGMP-grade ExPERT GTx Flow Electroporation instrument to its cell therapy platform, marking the company as the first cell therapy CDMO in China to possess this clinical-grade flow electroporation system.
Market Dynamics: Drivers & Restraints
Rising technological advancements
The rising technological advancements are significantly driving the growth of the electroporation instruments market and are expected to drive the market over the forecast period. Electroporation has become a pivotal technique in cancer treatment, particularly through electrochemotherapy. This method involves applying electrical pulses to tumors, increasing cell membrane permeability and allowing chemotherapeutic agents to enter cancer cells more effectively. Technological advancements have improved the precision and safety of this technique, leading to better treatment outcomes for patients with cutaneous and subcutaneous tumors.
For instance, in October 2024, AngioDynamics with the University College London Hospital (UCLH) launched a prospective registry study evaluating the long-term effects of the NanoKnife system for treating unifocal intermediate-risk prostate cancer. This NanoKnife system uses irreversible electroporation technology to treat tumors by delivering high-voltage electrical pulses that create tiny pores in cell membranes, leading to controlled cell death without harming surrounding tissues.
The development of gene editing technologies, such as CRISPR-Cas9, has increased the demand for electroporation instruments. Electroporation facilitates the efficient delivery of gene-editing components into cells, thereby advancing research and therapeutic applications. This has led to a surge in the adoption of electroporation instruments in genetic engineering and therapeutic interventions.
The high cost of the electroporation instruments
The high cost of electroporation instruments significantly hampers the growth of the market by limiting accessibility and adoption, particularly among smaller laboratories and research institutions with constrained budgets. For instance, the cost of the new electroporation systems typically ranges from $3,000 to $20,000, depending on the model, features and capabilities.
The substantial expense of electroporation instruments restricts their acquisition to well-funded laboratories and research centers, leaving smaller institutions unable to invest in such technologies. This disparity results in unequal access to advanced research tools, hindering the overall growth of the market. High equipment costs can lead to delays in research projects and the development of new therapies, as institutions may lack the necessary resources to procure and maintain these instruments. This slowdown in research activities can impede scientific progress and innovation within the field.
The global electroporation instruments market is segmented based on product type, application, end-user and region.
The instruments segment is expected to dominate the electroporation instruments market share
In the electroporation instruments market, the instruments segment including total electroporation systems, eukaryotic electroporation systems and microbial electroporation systems holds a dominant position over the accessories segment. This dominance is primarily due to the essential role that electroporation systems play in the process, as they generate the electrical pulses necessary for cell membrane permeabilization.
These electroporation instruments are the core devices for researchers to transfect even the most difficult cell types with excellent efficiency, cell recovery, and repeatability and these instruments apply electrical pulses to cells, facilitating the introduction of substances like DNA, RNA, or drugs. The market for these systems is substantial, with projections indicating significant growth.
For instance, in April 2023, Thermo Fisher Scientific launched the Invitrogen Neon NxT Electroporation System, which allows researchers to transfect even the most difficult cell types with excellent efficiency, cell recovery, and repeatability. Neon NxT electrodes are ideally positioned and have a small surface area to provide a more uniform electric field and keep physiological parameters stable during transfection. These advantages allow the intended alteration to occur in more cells, with fewer cells lost during the transfection process. The new system also has an enhanced feedback loop and ergonomic advancements for ease of usage.
North America is expected to hold a significant position in the electroporation instruments market share
North America especially the United States boosts a well-established healthcare system with state-of-the-art research laboratories, facilitating the adoption and integration of advanced technologies like electroporation instruments. The presence of major market players in the region particularly in the United States fosters innovations and advancements in electroporation instruments.
For instance, in March 2022, Thermo Fisher Scientific introduced a new large-volume electroporation system that allows cell therapy developers to more easily move from clinical development to commercial manufacturing. The Gibco CTS Xenon Electroporation System leverages a closed, highly flexible design to facilitate gene modifications without the use of traditional viral vectors. The electroporation approach enables the introduction of a payload into a cell by temporarily increasing cell permeability using an electrical pulse.
Asia-Pacific is growing at the fastest pace in the electroporation instruments market
The region is witnessing significant progress in biotechnology and molecular biology research. Electroporation instruments are essential for gene editing, protein production, and other biomedical applications. The expansion of research facilities and increased funding are contributing to the adoption of these technologies.
For instance, China has been leading investments in biotechnology with initiatives such as "Made in China 2025," which focuses on integrating advanced technologies into manufacturing and healthcare sectors. This initiative is expected to bolster the demand for electroporation instruments as part of broader biotechnological advancements.
As emerging economies in Asia-Pacific continue to develop their biotech sectors, there is an increasing demand for electroporation instruments for applications in biomedical research and therapeutic delivery56. Countries like India are investing heavily in science and technology, which further supports market growth
The major global players in the electroporation instruments market include Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Merck KGaA, MaxCyte, Lonza Group, BEX CO., LTD., Celetrix, LLC., Harvard Bioscience, Inc., Bulldog Bio, Inc., Spectrocell Inc. and among others.
The global electroporation instruments market report delivers a detailed analysis with 62 key tables, more than 53 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2024
LIST NOT EXHAUSTIVE